Jefferies Financial Group Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by equities research analysts at Jefferies Financial Group from $870.00 to $930.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 25.63% from the company’s previous close.

A number of other equities analysts also recently issued reports on REGN. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a research note on Thursday. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $809.50.

Regeneron Pharmaceuticals Trading Down 2.4%

REGN stock traded down $17.98 during mid-day trading on Thursday, reaching $740.29. The company had a trading volume of 623,687 shares, compared to its average volume of 829,401. The company has a market capitalization of $76.22 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20. The firm has a 50 day moving average of $785.06 and a 200 day moving average of $720.91. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 3,946 shares of company stock valued at $3,302,458. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides substantial upfront funding. Regeneron will receive $1 billion upfront and could earn up to $7 billion in milestones by adding several next-generation, long-acting immunology antibodies—including REGN20423—to its collaboration with Sanofi. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s pipeline and liquidity. Regeneron and Sanofi Expand Global Alliance
• Positive Sentiment: Promising obesity-treatment data support a potential differentiated role for trevogrumab. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of muscle loss associated with semaglutide in a predefined MRI substudy. Patients with low baseline lean mass appeared to receive particular benefit, potentially addressing a key concern with GLP-1 weight-loss drugs. Phase 2 COURAGE Trial
• Positive Sentiment: Ubamatamab showed encouraging early cancer efficacy. The MUC16xCD3 therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with recurrent low-grade serous ovarian cancer. The results could support further development in a cancer type with limited treatment options, although the sample was very small. Ubamatamab LGSOC Results
• Positive Sentiment: Analyst support improved. Argus upgraded REGN from “hold” to “buy” and assigned an $850 price target, implying meaningful upside based on the cited reference price. Argus Upgrade
• Neutral Sentiment: Analyst opinion remains mixed. RBC maintained a “Sector Perform” rating, suggesting the new announcements may already be partly reflected in the valuation and that investors may want additional clinical or commercial validation.
• Negative Sentiment: Pipeline results remain early-stage. Trevogrumab and ubamatamab still require additional clinical testing, while the Sanofi deal’s potential milestones are contingent on development and regulatory success. These factors may limit the immediate earnings impact and help explain why REGN has decreased despite positive news.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.